ADA Scientific Sessions 2025 Abstract
Glycemic Outcomes When Switching to iGlarLixi from Premixed Insulin (PI) in People with Type 2 Diabetes (T2D) by iGlarLixi Pen Subgroups—Post Hoc Analysis of Soli-SWITCH
Trial in peopleInterventions
Papers by Katarzyna Cypryk
1 result